DRUG RESPONSE MARKER IN BETA-1 ADRENERGIC RECEPTOR GENE

Details for Australian Patent Application No. 2002358293 (hide)

Owner MYRIAD GENETICS, INC

Inventors FILIGHEDDU, Fabiana; REID, Julia; WAGNER, Susanne

Pub. Number AU-A-2002358293

PCT Number PCT/US02/41504

PCT Pub. Number WO2003/057920

Priority 60/344,083 27.12.01 US

Filing date 27 December 2002

Wipo publication date 24 July 2003

International Classifications

C12Q 001/68 Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

G01N 033/53 Investigating or analysing materials by specific methods not covered by groups - Immunoassay

C12P 019/34 Preparation of compounds containing saccharide radicals

C07H 021/04 Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Event Publications

3 April 2003 Complete Application Filed

  Priority application(s): 60/344,083 27.12.01 US

4 September 2003 Application Open to Public Inspection

  Published as AU-A-2002358293

16 September 2004 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(f)/See Reg. 8.3(3). Examination has not yet been requested or directed for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002358294-Nasal devices including dilation and user communication and methods of using same

2002358292-Expression of protective antigens in transgenic chloroplasts and the production of improved vaccines